Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day
April 27, 2022 08:25 ET
|
Praxis Precision Medicines, Inc.
BOSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022
April 13, 2022 08:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference
April 04, 2022 16:01 ET
|
Neurona Therapeutics
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat chronic neurological disorders, today...
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy
April 01, 2022 08:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, April 01, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders,...
NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®
February 22, 2022 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Feb. 22, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced FDA Breakthrough Device Designation for its Monarch eTNS System® for...
Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562
January 18, 2022 09:00 ET
|
Praxis Precision Medicines, Inc.
PRAX-562 demonstrated robust preclinical antiseizure activity and exhibited an improved preclinical tolerability profile compared to standard-of-care Praxis expects to initiate a Phase 2 trial in the...
NeuroSigma Announces Promotion of Dr. Colin Kealey to President
January 11, 2022 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion of Dr. Colin Kealey to President. NeuroSigma is the developer...
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
December 03, 2021 10:01 ET
|
Neurona Therapeutics
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase...
Matt Tifft Joins Prestigious Forbes 30 Under 30 Class of 2022
December 03, 2021 09:00 ET
|
Live Fast Motorsports
MOORESVILLE, N.C., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Live Fast Motorsports co-owner Matt Tifft's career took a bit of a detour over the past few years, seeing the 25-year-old transition from the...
Rising Prevalence of Chronic Diseases Among People Across the Globe to Propel the Growth of the Global Neuromodulation Devices Market by 2026 – Exclusive Report [150 Pages] By Research Dive
December 01, 2021 09:00 ET
|
Research Dive
New York, USA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global neuromodulation devices market is expected to generate a revenue of $9,332.9 million,...